Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

Second-line treatment options for advanced/metastatic non-small cell lung cancer (NSCLC) patients are limited. We aimed to evaluate the efficacy and safety of docetaxel/sodium cantharidinate combination vs. either agent alone as second-line treatment for advanced/metastatic NSCLC patients with wild-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lin, Deng, Chao, Zhang, Hui, Weng, Jie, Wu, Youhua, Zeng, Shan, Tang, Tiegang, Cao, Peiguo, Qiu, Bo, Zhang, Li, Duan, Huaxin, Zhang, Bing, Zhang, Dong, Zhang, Taotao, Hu, Chunhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715707/
https://www.ncbi.nlm.nih.gov/pubmed/34976813
http://dx.doi.org/10.3389/fonc.2021.769037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715707/
https://www.ncbi.nlm.nih.gov/pubmed/34976813
http://dx.doi.org/10.3389/fonc.2021.769037

Ejemplares similares